Stachydrine, a potential drug for the treatment of cardiovascular system and central nervous system diseases.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
May 2023
Historique:
received: 18 12 2022
revised: 21 02 2023
accepted: 07 03 2023
medline: 3 4 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

Cardiovascular disease (CVD) is the leading cause of death globally and poses at significant challenge in terms of effective medical treatment. Leonurus japonicus Houtt, a traditional Chinese herb, is widely used in China for the treatment of obstetrical and gynecological disorders, including menstrual disorders, dysmenorrhea, amenorrhea, blood stasis, postpartum bleeding, and blood-related diseases such as CVD. Stachydrine, the main alkaloid component of Leonurus, has been shown to exhibit a wide range of biological activities including anti-inflammatory, antioxidant, anti-coagulant, anti-apoptotic, vasodilator, angiogenic promoter. Additionally, it has been demonstrated to have unique advantages in the prevention and treatment of CVD through regulation of various disease-related signaling pathways and molecular targets. In this comprehensive review, we examine the latest pharmacological effects and molecular mechanisms of Stachydrine in treating cardiovascular and cerebrovascular diseases. Our aim is to solid scientific basis for the development of new CVD drug formulations.

Identifiants

pubmed: 36940619
pii: S0753-3322(23)00277-9
doi: 10.1016/j.biopha.2023.114489
pii:
doi:

Substances chimiques

stachydrine S1L688345C
Drugs, Chinese Herbal 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

114489

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement All authors read and approved the final manuscript. They declare that they have no competing interests.

Auteurs

Li Liao (L)

Yibin Second People's Hospital - Yibin Hospital of West China Hospital of Sichuan University, Yibin 644000, China. Electronic address: liaoli19872021@163.com.

Yan Tang (Y)

Yibin Second People's Hospital - Yibin Hospital of West China Hospital of Sichuan University, Yibin 644000, China.

Bo Li (B)

Third Affiliated Hospital of Chengdu Medical College, Chengdu Pidu District People's Hospital, Chengdu 611730, China.

Jing Tang (J)

Yibin Second People's Hospital - Yibin Hospital of West China Hospital of Sichuan University, Yibin 644000, China.

Hong Xu (H)

Yibin Second People's Hospital - Yibin Hospital of West China Hospital of Sichuan University, Yibin 644000, China.

Ke Zhao (K)

Yibin Second People's Hospital - Yibin Hospital of West China Hospital of Sichuan University, Yibin 644000, China.

Xiaochun Zhang (X)

Yibin Second People's Hospital - Yibin Hospital of West China Hospital of Sichuan University, Yibin 644000, China. Electronic address: xcz2008xc@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH